Actinium Pharmaceuticals (NYSE:ATNM) Upgraded at StockNews.com

Actinium Pharmaceuticals (NYSE:ATNM) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

Separately, HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Actinium Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $7.40.

Actinium Pharmaceuticals Price Performance

Shares of NYSE ATNM traded up $0.03 during trading hours on Wednesday, hitting $1.52. 352,271 shares of the stock were exchanged, compared to its average volume of 500,097. Actinium Pharmaceuticals has a one year low of $1.03 and a one year high of $10.24. The company’s 50 day moving average is $1.27 and its 200 day moving average is $1.44. The firm has a market capitalization of $47.42 million, a P/E ratio of -1.09 and a beta of 0.10.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Northern Trust Corp raised its position in shares of Actinium Pharmaceuticals by 4.9% during the fourth quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock valued at $317,000 after buying an additional 11,812 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Actinium Pharmaceuticals by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after acquiring an additional 19,843 shares during the period. Vontobel Holding Ltd. acquired a new stake in shares of Actinium Pharmaceuticals during the 4th quarter worth approximately $32,000. Creative Financial Designs Inc. ADV raised its stake in shares of Actinium Pharmaceuticals by 42.7% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 91,007 shares of the company’s stock valued at $115,000 after purchasing an additional 27,222 shares in the last quarter. Finally, Barclays PLC boosted its stake in Actinium Pharmaceuticals by 323.0% during the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after buying an additional 32,784 shares in the last quarter. 27.50% of the stock is currently owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).